Esperion director granted 79,873 shares

Esperion Therapeutics director Jay Shepard reported an equity award of 79,873 shares of Common Stock.

Rhea-AI Filing Summary

Esperion Therapeutics director Jay Shepard reported an equity award of 79,873 shares of Common Stock. The shares were granted at no purchase price as a stock award and increase his direct holdings to 164,472 shares after the transaction.

The award vests in full on the earlier of May 28, 2027, or the company’s next annual meeting of stockholders following May 28, 2026, aligning vesting with future board service. This filing reflects compensation-related share acquisition rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 79,873 shares

Grant/Award 1 txn

Insider Shepard Jay

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	79,873	$0.00	$0.00

Holdings After Transaction: Common Stock — 164,472 shares (Direct)

Footnotes (1)

1. F1. The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

Key Figures

Stock award: 79,873 shares Award price: $0.00 per share Shares after transaction: 164,472 shares +1 more

4 metrics

Stock award 79,873 shares Common Stock grant to director on May 28, 2026

Award price $0.00 per share Grant, award, or other acquisition compensation

Shares after transaction 164,472 shares Total Common Stock directly held following grant

Vesting date May 28, 2027 Vests on this date or earlier at next annual meeting

Key Terms

Common Stock, Form 4, grant, award, or other acquisition, vests in full

4 terms

Common Stock financial

"Esperion Therapeutics director Jay Shepard reported an equity award of 79,873 shares of Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"This compensation grant increased his direct holdings to 164,472 shares following the transaction, according to the Form 4 insider filing details."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

grant, award, or other acquisition financial

"Code A indicates a grant, award, or other acquisition, and the 79,873 Common Stock shares were awarded at a price of $0.00 per share."

vests in full financial

"The award vests in full on the earlier of May 28, 2027, or the company’s next annual meeting of stockholders."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Esperion Therapeutics (ESPR) report for Jay Shepard?

Esperion Therapeutics director Jay Shepard reported receiving 79,873 shares of Common Stock as a stock award at no purchase price. This compensation grant increased his direct holdings to 164,472 shares following the transaction, according to the Form 4 insider filing details.

Is Jay Shepard’s Esperion (ESPR) Form 4 transaction a buy or a grant?

The Form 4 shows a grant, not an open-market buy or sell. Code A indicates a grant, award, or other acquisition, and the 79,873 Common Stock shares were awarded at a price of $0.00 per share as director compensation.

When do Jay Shepard’s newly granted Esperion (ESPR) shares vest?

The award vests in full on the earlier of May 28, 2027, or Esperion’s next annual meeting of stockholders following May 28, 2026. This means vesting depends either on time served or on the timing of the next annual meeting.

How many Esperion (ESPR) shares does Jay Shepard hold after this Form 4 grant?

After receiving the 79,873-share award, Jay Shepard directly holds 164,472 shares of Esperion Therapeutics Common Stock. This post-transaction figure comes from the Form 4 total shares following the transaction field for his direct ownership.

What does transaction code A mean in Jay Shepard’s Esperion (ESPR) Form 4?

Transaction code A in the Form 4 stands for a grant, award, or other acquisition. In this case, it reflects a stock award of 79,873 Common Stock shares to director Jay Shepard as compensation, rather than an open-market purchase by the insider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shepard Jay

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		79,873(1)	A	$0	164,472	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)